Track market-moving stories before they get noisy

Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.

Moderna co-founder and board chairman Noubar Afeyan discusses the phase three success of the Moderna-Merck cancer vaccine trial and explains how the vaccine targets unique mutations to help prevent melanoma recurrence on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #moderna #merck #cancer #vaccine #health #medicine #medical #melanoma #science #research #trial #biotech #technology #treatment #breakthrough #healthcare #innovation

Sydney Armani, CEO of AI Fintech World Group, discusses Nvidia (NVDA) continuing its climb after a stellar earnings report, with 2028 revenue projections soaring and its dominance in data center code and software cementing its leadership. Beyond Nvidia, emerging opportunities are drawing attention, including the space economy's focus on orbital data centers and satellite communication, where data infrastructure offers the real opportunity.

MRNA weekly chart shows recent bullish reversal signals. Source: TradingView An upside breakout signal will occur above Wednesday’s lower swing high of $156.42, with strength then confirmed on a move above $161.37. That should be followed by an advance above $176.66 and a continuation of the prior sharp advance into higher targets.

$170.47 Stands Between MRNA and a Larger Reversal Despite MRNA’s recent sharp advance, it still found resistance near the lower swing high of $170.47. A decisive continuation of the advance with a bull pennant breakout would trigger a bullish reversal signal of the prior downtrend. If a recovery of that level is sustained, and the bull pennant suggests that it may be, then the pennant projects another sharp move higher for MRNA. The more aggressive potential upside target derived from the pennant pattern is estimated near the lower swing high of $458.50 from September 2021.

Failure Below Support Would Change Everything At the same time, a drop below Tuesday’s low of $138.09 would confirm a decline below the lower rising boundary of the pennant, suggesting a breakdown from consolidation. A move below the recent higher swing low of $133.33 would then confirm the bearish signal, leading to a bearish reversal instead of bullish continuation of the trend.

If you’d like to know more about technical analysis and how traders use it, please visit our educational area.

3.9.2026 19:48

Americké akciové trhy dnes utěšeně rostou, když růst velkých technologických titulů a pokles dluhopisových výnosů převažují nad mírným zdražením ropy v reakci na další eskalaci konfliktu mezi USA a Íránem. Trhům pomohla slova guvernéra Fedu Christophera Wallera, že by byl ochoten podpořit ponechání sazeb beze změny, pokud bude inflace dál vykazovat pokrok směrem k dvouprocentnímu cíli. Peněžní trhy proto snížily sázky na zářijové zvýšení sazeb, i když Waller zároveň uvedl, že při silnějších inflačních datech by hike zvažoval. Investoři nyní čekají především na páteční srpnový report z trhu práce a následně na inflační data za srpen, která budou zveřejněna 11. září před zasedáním Fedu 15.–16. září. Geopolitickou nejistotu udržuje pokračující konflikt s Íránem, když podle zdrojů Írán odpálil střely na Kuvajt v reakci na americké bombardování z počátku týdne.

Růst táhnou především velké technologické a komunikační tituly. Microsoft (MSFT +2,62 %), Apple (AAPL +0,58 %), Meta Platforms ( META +3,71 %) a Nvidia (NVDA +2,24 %) po oznámení dohody o převzetí platformy Hugging Face za zhruba 13 mld. USD. Pozitivní nálada se ale neopírá jen o akcie — výnosy dluhopisů klesají, což pomáhá oceněním růstových titulů. Výnos desetiletého amerického dluhopisu se snižuje o 3 bazické body na 4,75 %. Euro roste o 0,4 % na 1,1639 USD. Ropa navzdory geopolitice roste jen mírně: WTI přidává 0,6 % na 91,57 USD za barel a Brent 0,1 % na 95,75 USD za barel. Zlato posiluje o 2,4 % na 4 486,61 USD za unci, bitcoin roste o 4,6 % na 80 973 USD a ether o 4,2 % na 2 495 USD.

Z jednotlivých titulů nejvíce vyčnívá Snowflake (SNOW), který skáče o 21 % po výrazně lepších kvartálních tržbách i zisku a zvýšení celoročního výhledu tržeb. Firma zároveň upozornila na rychlou adopci svého AI nástroje pro asistované programování. Naopak Broadcom (AVGO) klesá o 3,7 %, přestože výsledky překonaly odhady a firma očekává zdvojnásobení tržeb z AI čipů ve fiskálním roce končícím v roce 2028. Investory ale zklamal slabší celkový výhled tržeb. Hewlett Packard Enterprise  (HPE) odepisuje 3,6 %, i když výsledky překonaly odhady a firma zvýšila výhled díky poptávce po cloudu a AI, protože trh znepokojily dodavatelské limity a další rizika. Tyson Foods (TSN) ztrácí 7,4 % po snížení výhledu tržeb a provozního zisku kvůli tlaku na marže z volatilních cen skotu, zatímco Victoria’s Secret (VSXY) propadá o 14 %, když zisk překonal odhady, ale tržby zaostaly za očekáváním.

Index Dow Jones +1,22 % na 53707,52 b.
S&P 500 +1,04 % na 7746,61 b.
Nasdaq Composite +1,4 % na 26585,07 b.

Index S&P 500 +1,04 % na 7746,61 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Zbytná spotřeba +1,9 % Základní materiály -0,1 % Komunikační služby +1,8 % Energie 0 % Finanční sektor +1,4 % Zdravotní péče +0,1 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Robinhood Markets (HOOD) +15 % Ciena Corp (CIEN) -10,0 % Coinbase Global (COIN) +11 % Tyson Foods (TSN) -7,1 % Palantir Technologies (PLTR) +7,8 % Charter Communications (CHTR) -4,9 % Tesla (TSLA) +7,2 % Moderna (MRNA) -4,2 % Principal Financial Group (PFG) +6,7 % General Mills (GIS) -4,0 %
Martin Varecha
Fio banka, a.s.
Prohlášení

You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.

1.9.2026 22:06

Americké akciové indexy uzavřely úvodní seanci nového měsíce v negativním teritoriu v čele s technologickým Nasdaqem, který odepsal více než 1 %. Širší index S&P500 ztratil přes 0,7 % a tradiční index Dow Jones bezmála 0,8 % na pozadí zvýšeného geopolitického napětí na Blízkém východě, posunující cenu ropy (+5,6 %) nad hladinu 90 USD/barel. Vedle akcií se nedařilo ani dluhopisům, které oslabily napříč splatnostmi. Výnos 10letého vládního bondu končil téměř na úrovni 4,8 % (vs. 4,76 % včera). Ztrátový den vykázaly také drahé kovy. Zlato odepsalo 2,7 % se závěrem na 4328 USD/oz, stříbro pak o 3,6 % na 64,1 USD/oz.

Závěrečné hodnoty:

Dow Jones -0,79 % na 52767,59 b.
S&P 500 -0,71 % na 7631,54 b.
Nasdaq Composite -1,03 % na 26099,77 b.

Index S&P 500 -0,71 % na 7631,54 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Energie +1,5 % Zbytná spotřeba -1,9 % Utility +0,8 % Průmysl -1,4 % Zdravotní péče +0,7 % Základní materiály -1,4 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Moderna (MRNA) +9,9 % Axon Enterprise (AXON) -8,5 % Edison International (EIX) +8,9 % Cadence Design Systems (CDNS) -7,6 % PG&E Corp (PCG) +6,0 % Interactive Brokers Group (IBKR) -7,1 % HP (HPQ) +4,3 % Crowdstrike Holdings (CRWD) -6,9 % CF Industries Holdings (CF) +4,3 % Dell Technologies (DELL) -6,9 %
David Lamač
Fio banka, a.s.
Prohlášení

1.9.2026 20:24, AAPL, MRNA, CRWD, AXON

Americké akciové indexy úvodní zářijové seanci ztrácí v čele s technologickým Nasdaqem, který odepisuje 1 %, širší index S&P500 oslabuje o téměř 0,7 % a tradiční index Dow Jones o 0,8 %.

Děje se tak na pozadí opětovně zvýšeného geopolitického napětí na Blízkém východě. Nová vlna ostřelování iránských cílů v oblasti Hormuzského průlivu ze strany USA se přetavuje ve výrazný růst ceny ropy. Ta aktuálně atakuje hladinu 90 USD se ziskem téměř 5 %. Současně posunuje tržní výnosy na vyšší úrovně a apetit k rizikovým aktivům slábne, notabene v historicky slabším měsíci září.

Výnos 10letého vládního bondu se posunul k hladině 4,8 %, stahují se tak mračna na prudší zvyšování úrokových sazeb v USA. Aktuálně jsou do ledna zaceněna již téměř 2 zvýšení, v součtu tedy posun o 50 bazických bodů výše. Další růst dlouhodobých výnosů by mohl zesílit tlak na Trumpovu administrativu k přijetí dalších opatření. Americké ministerstvo financí vedené S. Bessentem již oznámilo zdvojnásobení objemu zpětných odkupů desetiletých až třicetiletých státních dluhopisů, oficiálně s cílem podpořit likviditu trhu.

Dnes oslabuje i další třída aktiv, a to drahé kovy. Zlato odepisuje 2,5 % na 4337,2 USD, stříbro ztrácí dokonce 3,2 % na 64,4 USD/oz.

Sektorově dnes logicky září energie s více než 1% ziskem. Výrazné ztráty naopak vykazuje segment zbytných statků (-1,9 %) a průmyslové společnosti.

Na korporátní úrovni dnes nejhorší výkonnost zaznamenává výrobce bezpečnostních technologií pro policii či záchranné složky, spol. Axon Enterprise (AXON -8,2 %) bez významných kurzotvorných zpráv. Předchozí tučné zisky koriguje také přední společnost se zaměřením na kyberbezpečnost, spol. Crowdstrike (CRWD -7,2 %) s našponovanou valuací. V čele růstu se dnes drží Moderna (MRNA +6,3 %), při pokračujícím zájmu investorů po nedávném zveřejnění závěrů studie protinádorové vakcíny. Solidní výkonnost zaznamenávají také akcie technologického gigantu Apple (AAPL +2,2 %) poté, co vedení společnosti převzal John Ternus, jenž nahradil Tima Cooka, který firmu úspěšně vedl od roku 2011, kdy ve funkci vystřídal spoluzakladatele Steva Jobse.

Index S&P 500 -0,69 % na 7633,16 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Energie +1,4 % Zbytná spotřeba -1,9 % Zdravotní péče +0,6 % Průmysl -1,5 % Nezbytná spotřeba +0,5 % Informační technologie -1,1 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Moderna (MRNA) +6,3 % Axon Enterprise (AXON) -8,2 % GoDaddy (GDDY) +4,0 % Crowdstrike Holdings (CRWD) -7,2 % Mosaic (MOS) +3,7 % Cadence Design Systems (CDNS) -7,1 % Howmet Aerospace (HWM) +3,7 % Ciena Corp (CIEN) -6,7 % S&P Global (SPGI) +3,5 % Palo Alto Networks (PANW) -6,1 %
David Lamač, Fio banka, a.s.

Moderna and Merck recently announced positive results from a late-stage clinical study of their melanoma treatment. In recent years, Moderna has broadened its reach beyond its first product: the coronavirus vaccine.

A woman with nearly $2 million saved sold her biotech shares when her boyfriend pressured her, watched the stock explode the next day, and then got dumped for it. Suze Orman had something to say about who actually came out…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Suze Orman closed a caller segment on the August 27 episode of her Women & Money podcast with a line aimed straight at a woman who had just been dumped: “Someday you’re going to realize that this breakup saved you far more than Moderna ever could have made you.” The caller, a 44-year-old woman with nearly $2 million in savings, had sold her Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares under pressure from a boyfriend who wanted her to go all in. The day after she sold, the stock exploded. He broke up with her for “failing” him.

Then the stock kept moving. That is where the story actually ends, and where the financial lesson lives.

What the One-Day Pop Actually Looked Like Moderna closed at $174 on August 19, 2026, up from $63 the prior session, a roughly 177% one-day move. Trading volume surged on cancer-trial news, and anyone who bought at that close was buying the loudest, most crowded print of the year.

The window in which selling early looked catastrophic has already narrowed. Moderna traded as low as $129 on August 20, roughly 27% below the $177 intraday high set on August 19. By August 26 the stock was back at $150, down 14% from the surge close, with a 6% drop on August 26 alone. CNBC’s post-market wrap that day led with hotter-than-expected inflation and Moderna falling.

Why Selling a Volatile Biotech After a Rally Was the Right Call Orman was right, and the stock proved her right within a week. Concentration risk is the mechanic here, and it does not disappear when the stock is going up. It gets worse. A single-name biotech that moves 177% in one session on trial data can round-trip a meaningful chunk of that move on the next headline.

Consider the alternate universe where she bought at the top. Nearly $2 million deployed at the August 19 close of $174 would be worth roughly $1.72 million by August 26 at $150, a paper loss of about $284,000 in five trading days. The intraday washout to $129 would have shown a temporary drawdown far larger than that.

She kept her roughly $2 million in retirement accounts, pension, and home equity intact. She dodged a single-name volatility bomb that was already leaking.

Position Size Decides Everything The factor that flips this story is how much of your investable money sits in one ticker. Orman’s rule from the same segment: “If you want to speculate in individual stocks, you are never, ever, ever use more than 5% of your investable money. And only money you could lose without changing your life.”

Apply that to the caller. Five percent of $2 million is $100,000. A 177% one-day pop on that slice would have added roughly $177,000 of paper gain, with the subsequent pullback giving back a portion of it. Life-changing in either direction? No. Survivable? Yes. Now run it at 100% of her net worth, which is what her boyfriend wanted. Against that backdrop, the 61% loss over five years is what happens to concentrated holders when the story changes. (Fencing off speculation with real sizing rules is the whole point of our free playbook on the 5% approach, here.)

Moderna is still an unprofitable biotech burning cash, with FY 2025 revenue of $1.94 billion, down 40% year over year, and 2026 guidance calling for year-end cash of $4.7 billion to $5.2 billion, down from $8.1 billion. Position size is what separates a fun speculation from a retirement-ending mistake.

What to Do With This Write down every individual stock you own and calculate what percent of your investable net worth each one represents. Anything above 5% in a speculative single name is where Orman would draw the line. For money earmarked for a home purchase or emergency fund, keep it in a money market account, not a biotech. Orman was explicit on this point with the caller. Before selling after a rally, ask what a 27% same-week drawdown would do to your plan. Moderna gave holders exactly that test on August 20. Never let a partner, a broker, or a podcast host tell you to concentrate money you cannot afford to lose. Orman’s own line to the caller: “You don’t need to become more comfortable taking more risk. You need to become comfortable trusting yourself.” The caller’s “mistake” got repriced by the market in five sessions. Selling a volatile single stock after a run is rarely the disaster it feels like in the moment. Owning too much of one is.

Contact [email protected] for any questions or corrections.

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have received an average rating of “Hold” from the twenty-three research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $80.5294.

A number of research firms have weighed in on MRNA. Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Loop Capital set a $135.00 price target on shares of Moderna in a research note on Wednesday, August 19th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Moderna in a report on Friday. They issued a “hold” rating on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $130.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. Finally, Barclays increased their price objective on Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, August 24th.

Read Our Latest Stock Analysis on MRNA

Insiders Place Their Bets In related news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider directly owned 67,468 shares in the company, valued at approximately $3,373,400. The trade was a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is owned by corporate insiders. Hedge Funds Weigh In On Moderna Large investors have recently modified their holdings of the business. TD Waterhouse Canada Inc. increased its position in Moderna by 2.6% during the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock worth $246,000 after buying an additional 85 shares in the last quarter. Assetmark Inc. lifted its position in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock valued at $41,000 after acquiring an additional 208 shares in the last quarter. New Mexico Educational Retirement Board lifted its position in shares of Moderna by 1.9% in the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock valued at $463,000 after acquiring an additional 300 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Moderna by 5.4% during the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock valued at $200,000 after acquiring an additional 348 shares during the last quarter. Finally, Empowered Funds LLC boosted its stake in shares of Moderna by 2.6% during the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after acquiring an additional 353 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Price Performance Shares of NASDAQ MRNA opened at $137.99 on Monday. The firm has a market capitalization of $55.09 billion, a P/E ratio of -17.27 and a beta of 0.91. The firm’s 50-day moving average price is $77.11 and its 200-day moving average price is $59.85. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna has a 1-year low of $22.28 and a 1-year high of $176.66.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the firm earned ($2.13) EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Equities research analysts anticipate that Moderna will post -6.11 earnings per share for the current fiscal year.

Key Stories Impacting Moderna Here are the key news stories impacting Moderna this week:

Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article About Moderna (Get Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Featured Stories Five stocks we like better than Moderna Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.

Moderna Stock Jumps as Wolfe Upgrade Puts Cancer Pipeline in Spotlight Summary

Moderna shares rallied as Wolfe Research upgraded the stock following encouraging late-stage results for its personalized cancer vaccine

Moderna MRNA shares climbed nearly 13% on Tuesday as investors weighed new analyst support following encouraging results from the company's late-stage cancer program.

The move came after Wolfe Research upgraded its view on the biotechnology company. BofA Securities also recently lifted its price target to $170, adding to the positive analyst momentum around the stock.

The focus is on Moderna's partnership with Merck and their Phase 3 INTerpath-001 study. The trial tested intismeran autogene, an individualized mRNA-based vaccine, together with Keytruda in patients with surgically treated high-risk melanoma.

Results released Aug. 19 showed the study achieved its main measure of recurrence-free survival. It also met a secondary goal involving the time before melanoma spread to other parts of the body.

The data could help reinforce Moderna's efforts to build a broader pipeline beyond its established vaccine business. Investors will likely look for additional clinical progress as the oncology program advances.

Positive cancer data and rising analyst support could provide another catalyst for Moderna shares, although further clinical developments remain important.

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Moderna Inc (NASDAQ:MRNA) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.

On August 25 at 10:03 AM EST, MRNA triggered a Power Inflow signal at a price of $151.75. MRNA’s price experienced some pullback after an initial price rise during the opening hour of trading, declining slightly prior to the Power Inflow alert. At the time of the signal, and shortly after, both the institutional and retail trading interest in MRNA shifted towards the buy side, leading to a steady rise in the stock price, eventually reaching a post-signal high price of $160.00 as of 2:00PM EST. This Power Inflow signal is aimed to be a bullish indication of institutional and retail interest, spotlighting where traders may be entering the market for the stock.

Understanding the Power Inflow Signal

The Power Inflow alert is a proprietary signal developed and provided by TradePulse. The alert is issued within the first two hours of the trading day, it highlights when there is a significant shift in order flow, specifically indicating that there’s been a strong trend toward buying activity. This suggests a high probability of bullish price movement for the rest of the day, making it a potentially strategic and opportune entry point for active traders.

Order flow analytics analyze real-time buying and selling trends by examining the volume, timing, and order size across both retail and institutional traders. These insights offer a more detailed understanding of price behavior and market sentiment for a stock, allowing the trader or institution to make the most informed decision possible.

MRNA Performance

At the time of the Power Inflow, MRNA was priced at $151.75. Following the signal:

• Intraday High As Of 2:00PM EST: $160.00 (+5.44%)

Today’s Power Inflow alert on MRNA is a strong example of how real-time order flow analytics can reveal bullish momentum, especially during a period where the stock price is stagnant or even declining. Any trader who bought shares of MRNA shortly after the Power Inflow signal could have realized a significant intraday gain, demonstrating the effectiveness of TradePulse’s Power Inflow signal and the advantage of monitoring order flow data. These short-term gains that followed the Power Inflow alert on MRNA highlight the value of order flow analytics in identifying bullish intraday activity along with a possible stock price reversal, offering traders a potentially advantageous buying opportunity.

This article is for informational purposes only and does not constitute financial advice, investment recommendations, or a solicitation to buy or sell securities. The analysis is based on stock order flow data, but accuracy is not guaranteed. Investing involves risk, including possible loss of principal, and past performance is not indicative of future results. Please consult a licensed financial advisor before making any investment decisions.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

SHANGHAI, CHINA - AUGUST 21, 2026 - A netizen is using his mobilephone to view Moderna logo and using his computer to view Moderna webpage in Shanghai, China on August 21, 2026. (Photo credit should read CFOTO/Future Publishing via Getty Images)

CFOTO/Future Publishing via Getty Images

This article was written by Doug Nathman, with research by his team at Trefis.

Moderna (MRNA) shares have surged over the past year, with the event that more than doubled its valuation in a single trading day occurring on August 19, 2026. On that date, Merck and Moderna announced that their Phase III melanoma trial of intismeran autogene in conjunction with KEYTRUDA had achieved its specified endpoints. Rather than focusing on what transpired on that specific day, the more pertinent question is what signs were observable beforehand. All of this information had been publicly available well prior to the readout, with some details dating back to early 2025.

Enrollment Had Already Concluded For The Melanoma TrialBy the time of its fourth-quarter 2024 report, Moderna had already communicated the crucial information: the Phase III adjuvant melanoma investigation involving intismeran, the personalized neoantigen treatment developed with Merck, was completely enrolled. This trial was among ten programs prioritized by the company for approval. A fully enrolled study no longer faces recruitment challenges; rather, it becomes a matter of counting participants and waiting for events to accumulate. The timing of its conclusion and the outcome remained uncertain.

Cost Reductions And A Collaborator Covered The WaitThe figures presented in the reports suggested a company under strain. As per its fiscal Q2 2025 results, the final quarterly report submitted before the surge commenced, trailing-twelve-month revenue was $3.06 billion, representing a 38.8% decline year over year, while the trailing operating margin was -107.1%. Alongside these results, Moderna announced it would be reducing its workforce by approximately 10%, and Merck was covering 50% of the expenses related to intismeran, as per management’s statements at that time, allowing the readout to be achieved without requiring total financial backing from the company.

Options Traders Had Stopped Anticipating An Unusually Large MovementBy August 8, 2025, implied volatility for Moderna had dropped to the 12th percentile of its trailing one-year range, a decline from the 34th percentile observed in early July 2025. A low percentile does not signal a bullish outlook; instead, it indicates that traders expected a smaller shift than what is typically seen, regardless of direction. The implied volatility was recorded at 56.9, with this percentile being calculated solely against the stock’s own historical performance over the past year.

What The Indicators Could ConveyOver the previous year, the stock yielded roughly 440%, in contrast to the approximately 21% return for the S&P 500. Pfizer saw an 18.4% increase while Alnylam Pharmaceuticals faced a 48.5% decrease in the same timeframe, indicating this was not a sector-wide reassessment. Following the melanoma data release, investors betting against the stock experienced unprecedented one-day losses. The indicators preceding the surge, all documented a year or more before the data arrived, outlined the nature of the risk rather than its outcome: enrollment had closed, funding was divided, and the market had ceased compensating for movements. The stock is currently priced around $145, at the higher end of its 52-week range of $22.36 to $174.38.

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt

Moderna will also purchase a hedge overlay intended to offset dilution up to a cap initially equal to at least a 150% premium to the stock price at pricing

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) ("Moderna"), today announced that it intends to offer, subject to market conditions and other factors, $2.0 billion aggregate principal amount of Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Moderna also intends to grant the initial purchasers of the notes an option to purchase, for settlement during a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $300.0 million aggregate principal amount of the notes.

The notes will be general senior unsecured obligations of Moderna. The notes will not bear regular interest and the principal amount of the notes will not accrete. Upon conversion, Moderna will pay or deliver, as the case may be, cash, shares of Moderna's common stock or a combination of cash and shares of Moderna's common stock, at Moderna's election. The final terms of the notes, including the initial conversion rate and certain other terms, will be determined at the time of the pricing of the notes.

Moderna expects to use the net proceeds from the offering (i) to pay the cost of the privately negotiated capped call transactions described below and (ii) for general corporate purposes, which may include the flexibility to invest in the growth of our oncology business and repayment of debt.

In connection with the pricing of the notes, Moderna expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or affiliates thereof and/or other financial institutions (the "option counterparties"). The capped call transactions will cover, subject to customary adjustments, the number of shares of Moderna's common stock that will initially underlie the notes. The capped call transactions are expected generally to reduce the potential dilution to Moderna's common stock upon any conversion of notes and/or offset any cash payments Moderna is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. Moderna anticipates that the cap price of the capped call transactions will initially represent a premium of at least 150% over the last reported sale price of the common stock on the pricing date of the offering. If the initial purchasers exercise their option to purchase additional notes, Moderna expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions with the option counterparties.

In connection with establishing their initial hedges of the capped call transactions, Moderna expects that the option counterparties or their respective affiliates will purchase shares of Moderna's common stock and/or enter into various derivative transactions with respect to Moderna's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Moderna's common stock or the notes at that time.

In addition, Moderna expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Moderna's common stock and/or purchasing or selling Moderna's common stock or other securities of Moderna in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so following any early conversion, repurchase or redemption of the notes, to the extent Moderna unwinds a corresponding portion of the capped call transactions or if Moderna otherwise unwinds all or a portion of the capped call transactions, and during the final observation period for the conversion of notes). This activity could also cause or avoid an increase or a decrease in the market price of Moderna's common stock or the notes, which could affect the ability of a holder of notes to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares and value of the consideration, if any, that a holder of notes will receive upon conversion of the notes.

The offer and sale of the notes and any shares of Moderna's common stock issuable upon conversion of the notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the proposed terms of the notes and capped call transactions, the timing, completion and size of the proposed offering of the notes and capped call transactions, the anticipated use of proceeds from the offering, and the grant of the option to the initial purchasers. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:

Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
[email protected]

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]

SOURCE: Moderna, Inc.

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt

Moderna has also purchased a hedge overlay intended to offset dilution up to a cap initially equal to a 175.0% premium to the stock price at pricing

CAMBRIDGE, MA / ACCESS Newswire / August 28, 2026 / Moderna, Inc. (NASDAQ:MRNA) ("Moderna"), today announced the pricing of $2.6 billion aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of $2.0 billion aggregate principal amount of the notes. Moderna has also granted the initial purchasers of the notes an option to purchase, for settlement during a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $400.0 million aggregate principal amount of the notes. The sale of the notes to the initial purchasers is expected to close on September 1, 2026, subject to customary closing conditions.

The notes will be general senior unsecured obligations of Moderna. The notes will not bear regular interest and the principal amount of the notes will not accrete. The notes will mature on March 1, 2032, unless earlier converted, redeemed or repurchased.

Moderna estimates that the net proceeds from the offering will be approximately $2,562.9 million (or approximately $2,957.3 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers' discount and estimated offering expenses. Moderna expects to use the net proceeds from the offering (i) to pay the approximately $285.0 million cost of the privately negotiated capped call transactions described below and (ii) for general corporate purposes, which may include the flexibility to invest in the growth of our oncology business and repayment of debt.

The notes will be convertible at the option of the holders in certain circumstances. Upon conversion, Moderna will pay or deliver, as the case may be, cash, shares of Moderna's common stock or a combination of cash and shares of Moderna's common stock, at Moderna's election.

The conversion rate will initially be 4.7487 shares of Moderna's common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $210.58 per share of Moderna's common stock). The initial conversion price represents a premium of approximately 47.5% over the last reported sale price of $142.77 per share of Moderna's common stock on the Nasdaq Global Select Market on August 27, 2026. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid special interest, if any. In addition, following certain corporate events that occur prior to the maturity date or if Moderna delivers a notice of redemption, it will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or convert its notes called (or deemed called, in the case of an optional redemption) for redemption during the related redemption period, as the case may be.

Moderna may not redeem the notes prior to September 6, 2029, except in the event of a cleanup redemption as described below. Moderna may redeem for cash all or any portion of the notes (subject to certain limitations), at its option, on a redemption date on or after September 6, 2029 and before the 21st scheduled trading day immediately prior to the maturity date if the last reported sale price of Moderna's common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Moderna provides the related notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date. In addition, subject to certain conditions, Moderna may redeem for cash all, but not less than all, of the notes at any time prior to the 21st scheduled trading day immediately preceding the maturity date if the aggregate principal amount of the notes that remains outstanding at such time is less than $100.0 million at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date.

If Moderna undergoes a "fundamental change" (as defined in the indenture that will govern the notes) then, subject to certain conditions and exceptions, holders may require Moderna to repurchase for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the fundamental change repurchase date.

In connection with the pricing of the notes, Moderna entered into privately negotiated capped call transactions with certain financial institutions (the "option counterparties"). The capped call transactions cover, subject to customary adjustments, the number of shares of Moderna's common stock initially underlying the notes. The capped call transactions are expected generally to reduce the potential dilution to Moderna's common stock upon any conversion of notes and/or offset any cash payments Moderna is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional notes, Moderna expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions with the option counterparties.

The cap price of the capped call transactions relating to the notes will initially be $392.6175, which represents a premium of 175.0% over the last reported sale price of Moderna's common stock on the Nasdaq Global Select Market on August 27, 2026, and is subject to certain adjustments under the terms of the capped call transactions.

In connection with establishing their initial hedges of the capped call transactions, Moderna expects that the option counterparties or their respective affiliates will purchase shares of Moderna's common stock and/or enter into various derivative transactions with respect to Moderna's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Moderna's common stock or the notes at that time.

In addition, Moderna expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Moderna's common stock and/or purchasing or selling Moderna's common stock or other securities of Moderna in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so following any early conversion, repurchase or redemption of the notes, to the extent Moderna unwinds a corresponding portion of the capped call transactions or if Moderna otherwise unwinds all or a portion of the capped call transactions, and during the final observation period for the conversion of notes). This activity could also cause or avoid an increase or a decrease in the market price of Moderna's common stock or the notes, which could affect the ability of a holder of notes to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares and value of the consideration, if any, that a holder of notes will receive upon conversion of the notes.

The notes were only offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act by means of a private offering memorandum. The offer and sale of the notes and any shares of Moderna's common stock issuable upon conversion of the notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.  

With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the timing and completion of the proposed offering of the notes and capped call transactions, the anticipated use of proceeds from the offering, and the grant of the option to the initial purchasers. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:

Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
[email protected]

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]

SOURCE: Moderna, Inc.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Argus Research analyst John Eade upgraded Moderna Inc (NASDAQ:MRNA) from Hold to Buy and announced a $180 price target. Moderna closed at $142.77 on Thursday. See how other analysts view this stock. Northland Capital Markets analyst Jeff Grampp upgraded Evolution Petroleum Corporation (AMEX:EPM) from Market Perform to Outperform and announced a $4 price target. Evolution Petroleum shares closed at $3.58 on Thursday. See how other analysts view this stock. CIBC analyst Robert Catellier upgraded Enbridge (TSX:ENB) from Neutral to Outperformer and raised the price target from C$77 to C$78. See how other analysts view this stock. Considering buying MRNA stock? Here’s what analysts think:

Photo via Shutterstock

Trending

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Shares of Moderna Inc. (NASDAQ:MRNA) are trading lower Monday morning, taking a breather following a multi-day surge driven by clinical trial success.

Moderna stock is trading near recent highs. What’s next for MRNA stock? Phase 3 Trial Success Validates mRNA Oncology PlatformThe major catalyst arrived last week, when Moderna and development partner Merck & Co. announced positive topline results from their Phase 3 INTerpath-001 trial. The study evaluated intismeran autogene, an experimental individualized mRNA cancer vaccine, in combination with Merck’s Keytruda for patients with high-risk Stage IIB-IV melanoma.

The trial met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival, demonstrating that the combination therapy significantly extended the time patients lived without cancer returning compared to Keytruda alone.

The successful readout represents the first positive Phase 3 trial result for a personalized mRNA cancer vaccine, providing a landmark proof-of-concept for Moderna’s platform beyond COVID-19 and respiratory treatments.

Following the Wednesday announcement, Moderna’s stock surged over 120% in a single trading session, sparking a wave of Wall Street analyst upgrades and adding tens of billions in market capitalization.

MRNA Shares Slide Monday MorningMRNA Price Action: Moderna shares were trading lower by 6.49% at $135.71 at the time of publication on Monday, according to Benzinga Pro data.

Read Next

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Bank of New York Mellon Corp acquired a new stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 1,701,675 shares of the company’s stock, valued at approximately $119,168,000. Bank of New York Mellon Corp owned approximately 0.43% of Moderna at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Moderna by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after purchasing an additional 399,487 shares during the period. Capital World Investors purchased a new stake in shares of Moderna in the fourth quarter worth about $378,299,000. Invesco Ltd. boosted its position in shares of Moderna by 15.7% in the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after acquiring an additional 1,115,131 shares during the period. Theleme Partners LLP boosted its position in shares of Moderna by 8.6% in the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock valued at $217,100,000 after acquiring an additional 626,420 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Moderna by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock valued at $136,290,000 after acquiring an additional 309,126 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In A number of analysts recently weighed in on the stock. Wolfe Research reaffirmed an “underperform” rating and set a $25.00 target price on shares of Moderna in a report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Brookline Capital Markets restated a “buy” rating on shares of Moderna in a research report on Wednesday. Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a report on Wednesday. Finally, Loop Capital set a $135.00 price objective on Moderna in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $69.50.

Get Our Latest Report on Moderna Insider Transactions at Moderna In other news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is currently owned by company insiders.

Moderna Stock Down 0.0% Shares of NASDAQ MRNA opened at $145.07 on Monday. The stock has a market capitalization of $57.92 billion, a P/E ratio of -18.16 and a beta of 0.91. Moderna, Inc. has a one year low of $22.28 and a one year high of $176.66. The firm’s 50 day simple moving average is $68.49 and its two-hundred day simple moving average is $56.19. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the prior year, the company earned ($2.13) EPS. The firm’s revenue was up 2.1% on a year-over-year basis. As a group, analysts expect that Moderna, Inc. will post -6.18 EPS for the current fiscal year.

Moderna News Roundup Here are the key news stories impacting Moderna this week:

Positive Sentiment: Investors are assigning substantial commercial potential to the cancer program. Jefferies reportedly estimates as much as $54 billion in peak global sales and raised its price target to $170, while coverage highlighted the possibility that the trial could establish an oncology opportunity comparable to Merck’s Keytruda franchise. Jefferies sees $54 billion peak sales for Moderna cancer therapy Positive Sentiment: The favorable Phase 3 outcome has triggered analyst upgrades, including William Blair moving Moderna to Outperform and Bank of America raising its rating to Neutral. The stock also reached a new 12-month high amid renewed enthusiasm for mRNA-based cancer treatments. Moderna raised to Outperform at William Blair Neutral Sentiment: Trading has been exceptionally volatile for a third consecutive session. Analysts attribute the sharp swings partly to heavy short interest and a subsequent short squeeze, while options activity suggests elevated volatility may persist even without new clinical information. Moderna rallies as mRNA trading whipsaws Negative Sentiment: Valuation concerns remain significant after the recent surge. JPMorgan raised its price target to $77 but retained an Underweight rating, implying substantial downside from current levels. Commentary also cautioned that the clinical success does not eliminate development, regulatory, manufacturing, commercialization, and pipeline risks for Moderna or other mRNA companies. JPMorgan raises Moderna price target but keeps Underweight rating About Moderna (Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Featured Articles Five stocks we like better than Moderna VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) shares saw unusually-strong trading volume on Friday after JPMorgan Chase & Co. raised their price target on the stock from $40.00 to $77.00. JPMorgan Chase & Co. currently has an underweight rating on the stock. Approximately 13,415,396 shares changed hands during trading, an increase of 29% from the previous session’s volume of 10,399,490 shares.The stock last traded at $148.35 and had previously closed at $133.32.

Several other research firms have also commented on MRNA. UBS Group boosted their price objective on Moderna from $50.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a report on Wednesday. The Goldman Sachs Group raised their target price on Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating on shares of Moderna in a research note on Monday, August 3rd. Finally, Bank of America upgraded Moderna from an “underperform” rating to a “neutral” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $69.50.

Check Out Our Latest Research Report on MRNA

Insider Activity In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This represents a 4.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.80% of the company’s stock. Moderna News Roundup Here are the key news stories impacting Moderna this week:

Positive Sentiment: Investors are assigning substantial commercial potential to the cancer program. Jefferies reportedly estimates as much as $54 billion in peak global sales and raised its price target to $170, while coverage highlighted the possibility that the trial could establish an oncology opportunity comparable to Merck’s Keytruda franchise. Jefferies sees $54 billion peak sales for Moderna cancer therapy Positive Sentiment: The favorable Phase 3 outcome has triggered analyst upgrades, including William Blair moving Moderna to Outperform and Bank of America raising its rating to Neutral. The stock also reached a new 12-month high amid renewed enthusiasm for mRNA-based cancer treatments. Moderna raised to Outperform at William Blair Neutral Sentiment: Trading has been exceptionally volatile for a third consecutive session. Analysts attribute the sharp swings partly to heavy short interest and a subsequent short squeeze, while options activity suggests elevated volatility may persist even without new clinical information. Moderna rallies as mRNA trading whipsaws Negative Sentiment: Valuation concerns remain significant after the recent surge. JPMorgan raised its price target to $77 but retained an Underweight rating, implying substantial downside from current levels. Commentary also cautioned that the clinical success does not eliminate development, regulatory, manufacturing, commercialization, and pipeline risks for Moderna or other mRNA companies. JPMorgan raises Moderna price target but keeps Underweight rating Hedge Funds Weigh In On Moderna Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MUFG Securities EMEA plc purchased a new stake in Moderna in the 2nd quarter valued at $28,000. Allied Private Wealth LLC purchased a new position in shares of Moderna during the 2nd quarter worth $30,000. Canton Hathaway LLC acquired a new position in shares of Moderna during the 1st quarter valued at about $31,000. Archer Investment Corp acquired a new position in shares of Moderna during the 2nd quarter valued at about $36,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The stock’s fifty day moving average is $68.49 and its 200-day moving average is $56.10. The stock has a market cap of $57.92 billion, a PE ratio of -18.16 and a beta of 0.91.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same period last year, the business earned ($2.13) earnings per share. Moderna’s revenue was up 2.1% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -6.18 EPS for the current year.

Moderna Company Profile (Get Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Further Reading Five stocks we like better than Moderna Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Sally Bakewell, Carol Massar and Emily Graffeo. -------- More on Bloomberg Television and Markets Like this video?

Shares of Moderna Inc (NASDAQ:MRNA) had their best day in history as a public company this week, with the stock soaring on positive news from a Phase 3 trial with Merck & Co (NYSE:MRK). The news was a major win for investors in the stock who have seen pressure on financials and shares since the end of the COVID-19 pandemic.

Here’s a look at how well investors who bought Moderna stock at its IPO and never sold have done.

•  What’s going on with MRNA stock today?

Years before Moderna’s Phase 3 positive news for its personalized mRNA cancer vaccine that uses the company’s mRNA-4157 (Intismeran autogene) in combination with Merck’s Keytruda, the company was a major winner from the COVID-19 vaccine.

Before both those major medical events was the private company Moderna, which was founded in 2010.

Armed with a pipeline of more than 20 programs and strong anticipation, the company went public in December 2018.

The IPO was at the time the largest biotech public offering in the U.S., with the company selling 26.3 million shares at $23 and raising $604.3 million. The offering has since been eclipsed twice, and Moderna now has the third-largest biotech IPO in U.S. history.

Investors who believed in the future of the company and its pipeline of mRNA treatment trials may have bought shares at IPO.

A $1,000 investment in Moderna stock at IPO could have bought 43.48 MRNA shares.

Today that investment would be worth $6,423.30, with a profit of $5,423.30 and a gain of 542.3%.

Compare that to the S&P 500, as tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY). A $1,000 investment in the SPY at the time could have bought 3.69 shares. That investment would be worth $2,828.09 today, up 182.8% over the same time period.

Of course, that’s if the position was held for the entire time from IPO to now. Investors may be upset if they’re still holding today and didn’t sell at 2021 highs.

Moderna stock hit an all-time high of $497.49 on Aug. 9, 2021. The 43.38 shares bought at IPO would have been worth $21,630.87 at that time, up 2,063.09%.

Read Next

Moderna’s Up and DownsModerna stock traded lower after its IPO and experienced periods of the stock dropping below the IPO price in 2018 and later in 2019.

Patient investors were rewarded when the COVID-19 pandemic put a giant spotlight on its COVID-19 vaccine. The company began working on the vaccine in March 2020 and it was later approved to distribute worldwide, showing a 94% efficacy rate.

That vaccine launch took the stock from around $19.50 at the beginning of 2020 to the $30s in March and the $50s in April. The stock continued to move higher and make new all-time highs ahead of the vaccine launch as optimism grew for its approval.

Shares were in the triple-digit range in November 2020 when the vaccine showed late-stage trial results, which led to approval in December 2020.

That approval helped boost the revenue of Moderna and sent shares even higher.

Moderna stock eventually peaked at $497.49 on Aug. 9, 2021.

Following the end of the COVID-19 pandemic, Moderna shares fell as investors were left wondering where the next revenue source would come from.

Revenue exploded thanks to the COVID-19 vaccine, rising from $803 million in 2020 to $18.5 billion in 2021 and $19.3 billion in 2022. Revenue declined sharply in the following years, falling to $1.9 billion in 2025.

What’s Next for ModernaModerna’s Phase 3 trial for patients with melanoma marked a major milestone for medicine this week and has investors excited about the future.

The results show that the combination and personalized mRNA treatment could keep advanced skin cancer from returning. The vaccine is designed specifically for each patient.

This marks the first Phase 3 win for mRNA cancer therapy and has provided optimism for the future of the treatment against skin cancer and the potential to advance other personalized vaccine options for cancer.

Merck and Moderna have nine Phase 2 and Phase 3 trials in the INTerpath clinical program that cover melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma, along with Phase 1 trials for lung, gastric, and pancreatic cancers.

Read Next

Photo pcruciatti / Shutterstock

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

21.8.2026 16:05, MRNA

Index Dow Jones +0,64 % na 53096,52 b. S&P 500 +0,32 % na 7665,44 b. Nasdaq Composite +0,09 % na 26089,54 b.

V úvodu obchodování se americké indexy obchodují v kladném teritoriu. Indexům dopomáhá uklidnění na dluhopisovém trhu. V reakci na růst kryptoměn výrazně posilují akcie Robinhood (+13 %) a Coinbase (+9,9 %). Výrazný růst dnes zaznamenávají akcie Moderny (+11 %). Trhy se momentálně připravují na příští týden, kdy ve středu oznámí své výsledky společnost Nvidia.

Index S&P 500 +0,32 % na 7665,44 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Základní materiály +2 % Utility -0,2 % Finanční sektor +1,2 % Informační technologie -0,1 % Zdravotní péče +0,6 % Nezbytná spotřeba +0 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Robinhood Markets (HOOD) +13 % Teradyne (TER) -2,7 % Moderna (MRNA) +11 % GoDaddy (GDDY) -2,3 % Coinbase Global (COIN) +9,9 % AppLovin Corp (APP) -2,1 % Freeport-McMoRan (FCX) +7,8 % Marvell Technology (MRVL) -1,7 % Albemarle Corp (ALB) +5,4 % Carvana (CVNA) -1,5 % Zdroj: Bloomberg

Jakub Němec
Fio banka, a.s.
Prohlášení

Související odkazy Wall Street otevírá čtvrtek v červeném Index S&P 500 v úvodu obchodování roste, akcie Moderny přidávají přes 110 % Moderna a Merck & Co. uspěly se studií protinádorové vakcíny Wall Street otevírá mírným růstem Wall Street se obchoduje smíšeně

After several years of lagging the market due to a weakening coronavirus business, Moderna (MRNA -23.55%) is finally getting its mojo back. The company's shares are up 402% this year, as of writing, thanks to significant clinical and regulatory progress. Yet Moderna likely hasn't peaked and may see further gains as it continues to advance its mRNA vaccine platform.

Image source: Getty Images.

Fantastic clinical trial results On Aug. 5, Moderna announced that the U.S. Food and Drug Administration (FDA) had approved mFLUSIVA, a flu vaccine. In clinical trials, mFLUSIVA proved more effective than marketed flu vaccines. It could help address an unmet need in this area. The current options aren't very good. Efficacy numbers range between 40% to 60% during the flu season, according to the U.S. Centers for Disease Control and Prevention.

This leaves many patients, particularly the elderly, at a significant risk of developing severe cases of the disease, potential hospitalization, and even death. mFLUSIVA could help improve things. The progress Moderna has made with mFLUSIVA this year contributed meaningfully to its strong performance.

But the biotech company hit another, arguably even more important, milestone. On Aug. 19, Moderna posted strong phase 3 results for its investigational personalized cancer vaccine, intismeran autogene. In the trial, intismeran autogene was administered alongside the cancer drug Keytruda in patients with advanced melanoma, and it led to a meaningful improvement in recurrence-free survival compared to Keytruda alone.

Moderna's shares soared by more than 100% on this news. That may seem odd, considering intismeran autogene had already posted encouraging phase 2 clinical trial data. However, a phase 2 win doesn't always translate to a strong performance in late-stage trials. Just as important, this trial win isn't just about intismeran autogene's potential. It also demonstrates the power of Moderna's mRNA platform and its ability to succeed beyond COVID-19 -- and beyond infectious diseases altogether.

Today's Change

(

-23.55

%) $

-41.06

Current Price

$

133.32

What the future holds Intismeran autogene is being investigated across several other cancers, including non-small cell lung cancer -- one of the leading causes of cancer death -- renal cell carcinoma, and bladder cancer. It could become an important product in oncology and generate significant revenue for Moderna, although it will have to share the profits with Merck (MRK -2.11%), its partner on this program. Further clinical wins across these other indications may push the stock even higher. Moderna also has a deep pipeline beyond intismeran autogene. The company is developing potential vaccines and therapies across other infectious diseases and cancers.

Some of its targets include HIV, Lyme disease, norovirus, multiple myeloma, and more. Moderna won't see every single one of these products be successful. No biotech company can achieve 100% success in developing novel medicines. But the company should see a decent success rate and transform its approved portfolio within five years. Moderna will then be able to move beyond its coronavirus business and deliver consistent revenue and earnings thanks to newer launches.

However, is the stock still attractive at current levels? After all, in addition to Moderna's poor financial results -- revenue growth has been unimpressive while the company remains unprofitable -- the stock now has a market cap of almost $63 billion. That said, it's important to remember that the market is valuing Moderna's entire pipeline, which features several potential breakthrough products even beyond intismeran autogene. The risk of occasional clinical setbacks is real, but the company's deep pipeline helps mitigate it.

Even with a modest 25% success rate for the company's current phase 2 programs, Moderna should be able to launch enough new products over the next five years to improve its financial results. So, the stock remains a buy, at least for investors willing to hold onto Moderna's shares for at least five years.